AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2020
Feb 19, 2020
31580_dirs_2020-02-19_2e41a088-9828-440a-9896-e0aa88f94abd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2020-02-14
Reporting Person: FOUSE JACQUALYN A (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-14 | Stock option (right to buy) | $51.51 | A | 137000 | Acquired | 2030-02-14 | Common stock (137000.0) | Direct |
| 2020-02-14 | Restricted stock units | $ | A | 34000 | Acquired | Common stock (34000.0) | Direct |
Footnotes
F1: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.